Related Experiment Videos
Aspirin, clopidogrel, and the surgeon
Insights
Continuing antiplatelet therapy, including aspirin and thienopyridines, is often recommended during the perioperative period to prevent thrombotic events. Physicians must carefully balance the risks of bleeding against the benefits of preventing cardiovascular and cerebrovascular events.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Antiplatelet therapy is increasingly used for cardiovascular and cerebrovascular event prevention.
- Perioperative management of antiplatelet therapy presents a clinical dilemma due to competing risks.
Purpose of the Study:
- To discuss the challenges and considerations for continuing antiplatelet therapy in the perioperative period.
- To provide guidance on balancing thrombotic and bleeding risks.
Main Methods:
- Review of current literature and guidelines on perioperative antiplatelet management.
- Analysis of the risks and benefits of continuing aspirin and thienopyridines.
Main Results:
- Aspirin continuation is favored due to its proven benefits in preventing thrombotic events.
- Thienopyridines (e.g., clopidogrel) should be maintained for recommended durations, especially post-stent placement.
- Maintaining antiplatelet therapy increases bleeding risk, necessitating careful individual patient assessment.
Conclusions:
- Perioperative guidelines offer limited clear solutions for managing antiplatelet therapy.
- Individualized patient management is crucial, weighing bleeding risk against thrombotic risk.
- Collaboration among healthcare providers is essential for optimal patient care.
Abstract:
The rising use of antiplatelet therapy for primary prevention and secondary prevention of cardiovascular and cerebrovascular events poses a dilemma for physicians in the perioperative period. The proven benefits of aspirin in preventing further thrombotic events in patients with prior ACS or stroke make it difficult to withdraw this therapy. The risk of hypercoagulability associated with surgery is also independent of antiplatelet withdrawal, but adds to the rebound effect of platelet responsiveness. Therefore, aspirin should be continued whenever feasible. Similarly, the use of thienopyridines such as clopidogrel, especially for the prevention of stent thrombosis, should be maintained for at least the recommended time frame, if not longer. It is recognized that maintaining antiplatelet therapy is also not without risk, as bleeding complications have been well documented. Unfortunately, current perioperative guidelines do not often provide a simple solution for management. Therefore, the risk of bleeding has to be weighed against the risk of thrombosis, and decisions should be made with all providers caring for the patient on an individual basis.